5 recruiting, 3 active not recruiting, 3 not yet recruiting. 7 Phase 1, 5 Phase 2, 4 Phase 3.
By phase and status
Follow Etentamig: new trials by email Literature Review of Etentamig trials Research Report on Etentamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | 220 | 2026-12-01 | 2026-05-20 |
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | 520 | 2026-11-30 | 2026-07-27 |
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis
Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | 370 | 2026-11-29 | 2026-08-28 |
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Recruiting | 38 | 2026-09-30 | 2026-10-05 |
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Etentamig, Lenalidomide, Daratumumab - Multiple Myeloma | Phase 2 / Phase 3 | Recruiting | 680 | 2026-01-08 | 2026-10-19 |
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Etentamig, Iberdomide - Multiple Myeloma | Phase 1 | Recruiting | 135 | 2025-08-07 | 2026-05-12 |
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Surzetoclax, Daratumumab, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | 325 | 2025-07-23 | 2026-10-27 |
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Etentamig, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | 602 | 2025-06-30 | 2026-10-19 |
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Etentamig, Carfilzomib, Pomalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 421 | 2024-05-19 | 2026-08-27 |
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Etentamig, Dexamethasone, Lenalidomide - Relapsed/Refractory Multiple Myeloma | Phase 1 | Active not recruiting | 283 | 2022-10-20 | 2026-08-14 |
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Etentamig - Relapsed/Refractory Multiple Myeloma | Phase 1 | Active not recruiting | 8 | 2022-03-24 | 2025-08-08 |
Conditions studied
Multiple Myeloma (9) · Neoplasms (5) · Amyloidosis (1) · Immunoglobulin Light-chain Amyloidosis (1) · Neoplasms, Plasma Cell (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Sponsors
AbbVie (9) · Mayo Clinic (1) · Universitätsklinikum Hamburg-Eppendorf (1)
Countries
United States (8) · Japan (7) · Australia (6) · France (5) · Germany (5) · Italy (4) · Spain (4) · United Kingdom (4) · Canada (3) · Israel (3) · Norway (3) · Poland (3) · Portugal (3) · Belgium (2) · Hungary (2)
Top investigators
Prashant Kapoor, MD (1)
NIH funding
2023 (2), 2025 (2)